{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:06:49Z","timestamp":1761653209036,"version":"build-2065373602"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery\/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We reviewed retrospectively children younger than 2 years with newly diagnosed RMS treated from January 2002 until December 2022 at King Hussein Cancer Center. Demographics, clinical characteristics, and outcomes were analyzed. Statistical analysis included descriptive statistics and survival analysis using Kaplan-Meier methods. All cases were reviewed in a multidisciplinary clinic comprising experienced radiotherapists and surgeons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 34 cases of RMS in patients younger than 2 years at diagnosis. The median age was 13 months, with 70.6% males. The most common tumor site was bladder\/prostate (N=13, 38%), followed by orbit (N=5, 14.7%), the predominant subtype was embryonal (N=30). Risk-stratification categorized 17.6% as low-risk and 79.4% as intermediate-risk. Twenty-five patients had tumors &gt;5\u00a0cm, with metastasis in 6 (17.6%). All patients received neo-adjuvant chemotherapy, local control was by radiotherapy only (n=12, 35.3%), combined surgery and radiotherapy (n=11, 32.4%), or surgery alone (n=3, 8.8%). The 5-year event-free and overall survival rates were 55.1% and 57.5%, respectively. Fourteen patients experienced relapse\/progression, with local relapse the most common pattern. TNM stage, clinical group, metastasis at diagnosis, and radiotherapy use significantly impacted survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Children under 2 years of age with RMS face significant challenges, with high local recurrence rates and suboptimal survival outcomes compared with older pediatric patients. Our findings highlight the need for tailored treatment approaches that balance effective local control with minimizing long-term toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003124","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:00:10Z","timestamp":1757451610000},"page":"414-421","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Rhabdomyosarcoma in Pediatric Patients Under 2 Years: Clinical Features and Outcome"],"prefix":"10.1097","volume":"47","author":[{"given":"Mohammad","family":"Alzoubi","sequence":"first","affiliation":[{"name":"School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Diab","sequence":"additional","affiliation":[{"name":"School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Odeh","sequence":"additional","affiliation":[{"name":"School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Al-Assaf","sequence":"additional","affiliation":[{"name":"School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrouq","family":"Amer","sequence":"additional","affiliation":[{"name":"Pediatric"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Darweesh","sequence":"additional","affiliation":[{"name":"Pediatric"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Kh.","family":"Ibrahimi","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Boheisi","sequence":"additional","affiliation":[{"name":"Nursing, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iyad","family":"Sultan","sequence":"additional","affiliation":[{"name":"Department of Pediatric, The University of Jordan"},{"name":"Pediatric"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4803-1976","authenticated-orcid":false,"given":"Hadeel","family":"Halalsheh","sequence":"additional","affiliation":[{"name":"Department of Pediatric, The University of Jordan"},{"name":"Pediatric"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"R1-20251028","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.jss.2011.03.001","article-title":"Rhabdomyosarcoma in children: a SEER population based study","volume":"170","author":"Perez","year":"2011","journal-title":"J Surg Res"},{"key":"R2-20251028","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1002\/cncr.25887","article-title":"Rhabdomyosarcoma in infants less than one year of age: a report from the Children\u2019s Oncology Group","volume":"117","author":"Malempati","year":"2011","journal-title":"Cancer"},{"key":"R3-20251028","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/cncr.24465","article-title":"Trends in childhood rhabdomyosarcoma incidence and survival in the United States (1975\u20132005)","volume":"115","author":"Ognjanovic","year":"2009","journal-title":"Cancer"},{"key":"R4-20251028","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers12071758","article-title":"Recent advances and challenges in the treatment of rhabdomyosarcoma","volume":"12","author":"Miwa","year":"2020","journal-title":"Cancers"},{"key":"R5-20251028","doi-asserted-by":"crossref","first-page":"439213","DOI":"10.1155\/2013\/439213","article-title":"Outcome of rhabdomyosarcoma in first year of life: Children\u2019s Cancer Hospital 57357 Egypt","volume":"2013","author":"El Nadi","year":"2013","journal-title":"Sarcoma"},{"issue":"suppl_15","key":"R6-20251028","doi-asserted-by":"crossref","first-page":"10004","DOI":"10.1200\/jco.2014.32.15_suppl.10004","article-title":"Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC\/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): a report from the Children\u2019s Oncology Group Soft Tissue Sarcoma Committee","volume":"32","author":"Hawkins","year":"2014","journal-title":"J Clin Oncol"},{"key":"R7-20251028","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/cncr.11357","article-title":"Rhabdomyosarcoma in infants younger than one year old","volume":"97","author":"Ferrari","year":"2003","journal-title":"Cancer"},{"key":"R8-20251028","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/pbc.10441","article-title":"Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children\u2019s Oncology Group","volume":"42","author":"Joshi","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20251028","first-page":"e1503","article-title":"Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: analysis of surveillance, epidemiology and end results data from 2000 to 2016","volume":"5","author":"Rees","year":"2022","journal-title":"Cancer Rep"},{"key":"R10-20251028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2018.08.017","article-title":"Treatment approach and outcomes in infants with localized rhabdomyosarcoma: a report from the soft tissue Sarcoma Committee of the Children\u2019s Oncology Group","volume":"103","author":"Bradley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-20251028","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/cancers15082296","article-title":"Clinical characteristics, treatment considerations, and outcomes of infants with rhabdomyosarcoma","volume":"15","author":"Yan","year":"2023","journal-title":"Cancers"},{"key":"R12-20251028","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/cncr.30613","article-title":"Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with increased risk of recurrence: a report from the Soft Tissue Sarcoma Committee of the Children\u2019s Oncology Group","volume":"123","author":"Walterhouse","year":"2017","journal-title":"Cancer"},{"key":"R13-20251028","doi-asserted-by":"crossref","first-page":"e27652","DOI":"10.1002\/pbc.27652","article-title":"Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS)","volume":"66","author":"Sparber-Sauer","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20251028","first-page":"206","article-title":"Localised rhabdomyosarcoma in infants (<12 months) and young children (12-36 months of age) treated on the EpSSG RMS 2005 study","volume":"160","author":"Slater","year":"2022","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"R15-20251028","doi-asserted-by":"crossref","first-page":"e29511","DOI":"10.1002\/pbc.29511","article-title":"An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children\u2019s Oncology Group clinical trials","volume":"69","author":"Haduong","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"R16-20251028","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2018.77.9694","article-title":"Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"36","author":"Hawkins","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-20251028","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2014.55.6787","article-title":"Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the soft tissue sarcoma Committee of the Children\u2019s Oncology Group","volume":"32","author":"Walterhouse","year":"2014","journal-title":"J Clin Oncol"},{"key":"R18-20251028","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/pbc.24241","article-title":"Improved care of rhabdomyosarcoma in Jordan using less intensive therapy","volume":"60","author":"Al-Jumaily","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R19-20251028","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/1097-0142(19861215)58:12<2606::AID-CNCR2820581209>3.0.CO;2-T","article-title":"Infants younger than 1 year of age with rhabdomyosarcoma","volume":"58","author":"Ragab","year":"1986","journal-title":"Cancer"},{"key":"R20-20251028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ajco.13975","article-title":"Clinicopathological and treatment response characteristics of updated rhabdomyosarcoma histomolecular subtypes: an Asian population-based study","volume":"21","author":"How","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"R21-20251028","first-page":"674523","article-title":"Epidemiological characteristics and survival studies of rhabdomyosarcoma in East Egypt: a five-year multicenter study","volume":"2012","author":"Badr","year":"2012","journal-title":"Int Sch Res Not"},{"key":"R22-20251028","doi-asserted-by":"crossref","first-page":"E984","DOI":"10.1002\/lary.28785","article-title":"Role of surgery in rhabdomyosarcoma of the head and neck in children","volume":"131","author":"Dombrowski","year":"2021","journal-title":"Laryngoscope"},{"key":"R23-20251028","first-page":"17196","article-title":"Clinical characteristics and prognosis of childhood rhabdomyosarcoma: a ten-year retrospective multicenter study","volume":"8","author":"Ma","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R24-20251028","first-page":"e1683","article-title":"Rhabdomyosarcoma in children: retrospective analysis from a single tertiary care center in Saudi Arabia","volume":"6","author":"Markiz","year":"2022","journal-title":"Cancer Rep"},{"key":"R25-20251028","doi-asserted-by":"crossref","first-page":"100139","DOI":"10.1016\/j.yjpso.2024.100139","article-title":"Management and outcomes of children with rhabdomyosarcoma in a low-to-middle-income country: a first report from Chris Hani Baragwanath Academic Hospital, South Africa","volume":"6","author":"Jacobson","year":"2024","journal-title":"J Pediatr Surg Open"},{"key":"R26-20251028","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3109\/08880018.2012.676721","article-title":"Rhabdomyosarcoma treatment and outcome at a multidisciplinary pediatric cancer center in Lebanon","volume":"29","author":"Salman","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"R27-20251028","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.3892\/ol.2016.5072","article-title":"Management of pediatric head and neck rhabdomyosarcoma: a case-series of 36 patients","volume":"12","author":"Radzikowska","year":"2016","journal-title":"Oncol Lett"},{"key":"R28-20251028","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/S2214-109X(23)00053-0","article-title":"Delays in cancer care for children in low-income and middle-income countries: development of a composite vulnerability index","volume":"11","author":"Cotache-Condor","year":"2023","journal-title":"Lancet Glob Health"},{"key":"R29-20251028","doi-asserted-by":"crossref","first-page":"e30175","DOI":"10.1002\/pbc.30175","article-title":"Determinants of delayed childhood cancer care in low- and middle-income countries: a systematic review","volume":"70","author":"Cotache-Condor","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"R30-20251028","doi-asserted-by":"crossref","first-page":"101727","DOI":"10.1016\/j.canep.2020.101727","article-title":"Childhood cancer care in the Middle East, North Africa, and West\/Central Asia: a snapshot across five countries from the POEM network","volume":"71","author":"Basbous","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"R31-20251028","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2478\/raon-2020-0059","article-title":"Treatment of rhabdomyosarcoma in children and adolescent from four low health expenditures average rates countries","volume":"54","author":"Mazic","year":"2020","journal-title":"Radiol Oncol"},{"key":"R32-20251028","doi-asserted-by":"crossref","first-page":"e244170","DOI":"10.1001\/jamanetworkopen.2024.4170","article-title":"Germline genetic testing and survival outcomes among children with rhabdomyosarcoma","volume":"7","author":"Martin-Giacalone","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:01:55Z","timestamp":1761652915000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003124","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"type":"print","value":"1077-4114"},{"type":"electronic","value":"1536-3678"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"2025-04-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}